Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Hemodynamic Mechanisms of Exercise-Induced Pulmonary Hypertension in Patients with Lymphangioleiomyomatosis: The Role of Exercise Stress Echocardiography.

Sonaglioni A, Baravelli M, Cassandro R, Torre O, Elia D, Anzà C, Harari S.

J Am Soc Echocardiogr. 2018 Mar 28. pii: S0894-7317(18)30096-8. doi: 10.1016/j.echo.2018.02.004. [Epub ahead of print]

PMID:
29605474
2.

A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis.

Harari S, Caminati A, Poletti V, Confalonieri M, Gasparini S, Lacedonia D, Luppi F, Pesci A, Sebastiani A, Spagnolo P, Vancheri C, Balestro E, Bonifazi M, Cerri S, De Giacomi F, Della Porta R, Foschino Barbaro MP, Fui A, Pasquinelli P, Rosso R, Tomassetti S, Specchia C, Rottoli P; for the ILDINET (Interstitial Lung Diseases Italian Network).

Respiration. 2018 Mar 27. doi: 10.1159/000487711. [Epub ahead of print]

PMID:
29587263
3.

Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension.

Farina S, Bruno N, Agalbato C, Contini M, Cassandro R, Elia D, Harari S, Agostoni P.

Int J Cardiol. 2018 May 15;259:178-182. doi: 10.1016/j.ijcard.2017.11.023.

PMID:
29579597
4.

Validation of multidisciplinary diagnosis in IPF.

Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group.

Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. No abstract available.

PMID:
29413085
5.

The LAM Lung Cell and Its Human Cell Models.

Steagall WK, Pacheco-Rodriguez G, Darling TN, Torre O, Harari S, Moss J.

Am J Respir Cell Mol Biol. 2018 Feb 6. doi: 10.1165/rcmb.2017-0403TR. [Epub ahead of print]

PMID:
29406787
6.

Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A.

Virchows Arch. 2018 Feb 1. doi: 10.1007/s00428-018-2307-3. [Epub ahead of print]

PMID:
29388013
7.

The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy.

Conti S, Harari S, Caminati A, Zanobetti A, Schwartz JD, Bertazzi PA, Cesana G, Madotto F.

Eur Respir J. 2018 Jan 25;51(1). pii: 1700397. doi: 10.1183/13993003.00397-2017. Print 2018 Jan.

PMID:
29371377
8.

Severe idiopathic pulmonary fibrosis: A clinical approach.

Lipsi R, Mazzola D, Caminati A, Elia D, Lonati C, Harari S.

Eur J Intern Med. 2018 Apr;50:20-27. doi: 10.1016/j.ejim.2018.01.014. Epub 2018 Feb 1. Review.

PMID:
29361476
9.

Pulmonary hypertension: a paradigm for rare pulmonary diseases.

Harari S.

Eur Respir Rev. 2017 Dec 20;26(146). pii: 170120. doi: 10.1183/16000617.0120-2017. Print 2017 Dec 31. No abstract available.

10.

Recent advances in managing idiopathic pulmonary fibrosis.

Scelfo C, Caminati A, Harari S.

F1000Res. 2017 Nov 27;6:2052. doi: 10.12688/f1000research.10720.1. eCollection 2017. Review.

11.

Endocrine and metabolic assessment in adults with Langerhans cell histiocytosis.

Montefusco L, Harari S, Elia D, Rossi A, Specchia C, Torre O, Adda G, Arosio M.

Eur J Intern Med. 2017 Nov 29. pii: S0953-6205(17)30471-5. doi: 10.1016/j.ejim.2017.11.011. [Epub ahead of print]

PMID:
29198444
12.

Classification of pulmonary neuroendocrine tumors: new insights.

Pelosi G, Sonzogni A, Harari S, Albini A, Bresaola E, Marchiò C, Massa F, Righi L, Gatti G, Papanikolaou N, Vijayvergia N, Calabrese F, Papotti M.

Transl Lung Cancer Res. 2017 Oct;6(5):513-529. doi: 10.21037/tlcr.2017.09.04. Review.

13.

New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.

Torre O, Elia D, Caminati A, Harari S.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170042. doi: 10.1183/16000617.0042-2017. Print 2017 Sep 30. Review.

14.

Severe idiopathic pulmonary fibrosis: what can be done?

Caminati A, Cassandro R, Torre O, Harari S.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170047. doi: 10.1183/16000617.0047-2017. Print 2017 Sep 30. Review.

15.

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.

Caliò A, Eble JN, Hes O, Martignoni G, Harari SE, Williamson SR, Brunelli M, Osunkoya AO, Wang L, Comperat E, Lopez-Beltran A, Wang M, Zhang S, Curless KL, Post KM, Chang HY, Luchini C, Baldrige LA, MacLennan GT, Montironi R, Grignon DJ, Cheng L.

Oncotarget. 2016 Aug 8;8(33):54096-54105. doi: 10.18632/oncotarget.11117. eCollection 2017 Aug 15.

16.

Rare pulmonary diseases: a common fight.

Harari S, Humbert M.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170059. doi: 10.1183/16000617.0059-2017. Print 2017 Sep 30. No abstract available.

17.

Current understanding and management of pulmonary Langerhans cell histiocytosis.

Vassallo R, Harari S, Tazi A.

Thorax. 2017 Oct;72(10):937-945. doi: 10.1136/thoraxjnl-2017-210125. Epub 2017 Jul 8. Review.

PMID:
28689173
18.

Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimens.

Harari SE, Sassoon DJ, Priemer DS, Jacob JM, Eble JN, Caliò A, Grignon DJ, Idrees M, Albany C, Masterson TA, Hanna NH, Foster RS, Ulbright TM, Einhorn LH, Cheng L.

Urol Oncol. 2017 Oct;35(10):605.e9-605.e16. doi: 10.1016/j.urolonc.2017.05.018. Epub 2017 Jun 21.

PMID:
28647396
19.

Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?

Harari S, Elia D, Humbert M.

Chest. 2018 Jan;153(1):217-223. doi: 10.1016/j.chest.2017.06.008. Epub 2017 Jun 16. Review.

PMID:
28629920
20.

The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps.

Harari S, Cassandro R, Torre O.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):659-660. doi: 10.1164/rccm.201702-0272LE. No abstract available.

PMID:
28288282
21.

Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada.

Harari S, Caminati A, Madotto F, Conti S, Cesana G.

Eur Respir J. 2017 Jan 25;49(1). pii: 1601504. doi: 10.1183/13993003.01504-2016. Print 2017 Jan. No abstract available.

PMID:
28122864
22.

Out with the old, in with the new for the European Respiratory Review.

Harari S.

Eur Respir Rev. 2017 Jan 3;26(143). pii: 160118. doi: 10.1183/16000617.0118-2016. Print 2017 Jan. No abstract available.

23.

The revolution of pulmonary arterial hypertension.

Harari S.

Eur Respir Rev. 2016 Dec;25(142):361-363. doi: 10.1183/16000617.0102-2016. No abstract available.

24.

99mTc-Sestamibi Avid Soft Tissue Lesions in Rosai-Dorfman Disease.

Wong PK, Lee DJ, Harari S, Barron BJ.

Clin Nucl Med. 2016 Dec;41(12):e508-e510.

PMID:
27824326
25.

Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective.

Bassi I, Hollis G, Cottin V, Harari S, Zwanenburg E, Veltkamp M, Casanova A, Fletcher M, Masefield S, Powell P, Boyd J.

ERJ Open Res. 2016 Apr 21;2(2). pii: 00102-2015. eCollection 2016 Apr.

26.

Adding new perspectives to the European Respiratory Review.

Harari S.

Eur Respir Rev. 2016 Sep;25(141):221-2. doi: 10.1183/16000617.0045-2016. No abstract available.

27.

Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.

Harari S, Elia D, Torre O, Bulgheroni E, Provasi E, Moss J.

Chest. 2016 Aug;150(2):e29-32. doi: 10.1016/j.chest.2016.02.654.

PMID:
27502989
28.

Data sharing: When better may be the enemy of good.

Harari S.

Eur J Intern Med. 2016 Sep;33:e28-9. doi: 10.1016/j.ejim.2016.06.003. Epub 2016 Jun 28. No abstract available.

PMID:
27363305
29.

Thoracic involvement in generalised lymphatic anomaly (or lymphangiomatosis).

Luisi F, Torre O, Harari S.

Eur Respir Rev. 2016 Jun;25(140):170-7. doi: 10.1183/16000617.0018-2016. Review.

30.

Why we should care about ultra-rare disease.

Harari S.

Eur Respir Rev. 2016 Jun;25(140):101-3. doi: 10.1183/16000617.0017-2016. No abstract available.

31.

Toward better management of rare and orphan pulmonary diseases.

Harari S, Humbert M.

Eur Respir J. 2016 May;47(5):1334-5. doi: 10.1183/13993003.00390-2016. No abstract available.

32.

The goal is to go further and do better: but how?

Harari S.

Eur Respir Rev. 2016 Mar;25(139):1-3. doi: 10.1183/16000617.0094-2015. No abstract available.

33.

Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.

Harari S, Madotto F, Caminati A, Conti S, Cesana G.

PLoS One. 2016 Feb 3;11(2):e0147072. doi: 10.1371/journal.pone.0147072. eCollection 2016.

34.

Primary mucinous adenocarcinoma of the female urethra: a contemporary clinicopathologic analysis.

Harari SE, Cheng L, Osunkoya AO.

Hum Pathol. 2016 Jan;47(1):132-7. doi: 10.1016/j.humpath.2015.09.014. Epub 2015 Sep 30.

PMID:
26552875
35.

The changing face of a rare disease: lymphangioleiomyomatosis.

Harari S, Torre O, Cassandro R, Moss J.

Eur Respir J. 2015 Nov;46(5):1471-85. doi: 10.1183/13993003.00412-2015. Epub 2015 Sep 24. Review.

36.

Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation.

Caminati A, Madotto F, Cesana G, Conti S, Harari S.

Eur Respir Rev. 2015 Sep;24(137):436-44. doi: 10.1183/16000617.0040-2015. Review.

37.

Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.

Harari S, Caminati A.

Eur Respir Rev. 2015 Sep;24(137):420-7. doi: 10.1183/16000617.0042-2015. Review.

38.

Pulmonary hypertension in patients with chronic myeloproliferative disorders.

Adir Y, Elia D, Harari S.

Eur Respir Rev. 2015 Sep;24(137):400-10. doi: 10.1183/16000617.0041-2015. Review.

39.

Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?

Harari S, Humbert M, Blasi F, Collard HR, Matucci-Cerinic M, Simonneau G, Vancheri C, Wells AU, Cottin V.

Eur Respir Rev. 2015 Sep;24(137):375-7. doi: 10.1183/16000617.0051-2015. No abstract available.

40.

Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy.

Kandula S, Switchenko JM, Harari S, Fasola C, Mister D, Yu DS, Zelnak AB, Torres MA.

Int J Breast Cancer. 2015;2015:147476. doi: 10.1155/2015/147476. Epub 2015 Jul 21.

41.

Smoking-related idiopathic interstitial pneumonia: A review.

Margaritopoulos GA, Harari S, Caminati A, Antoniou KM.

Respirology. 2016 Jan;21(1):57-64. doi: 10.1111/resp.12576. Epub 2015 Jul 2. Review.

42.

Effects on health of air pollution: a narrative review.

Mannucci PM, Harari S, Martinelli I, Franchini M.

Intern Emerg Med. 2015 Sep;10(6):657-62. doi: 10.1007/s11739-015-1276-7. Epub 2015 Jul 2. Review.

PMID:
26134027
43.

Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.

Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP.

Eur Respir J. 2015 Sep;46(3):783-94. doi: 10.1183/09031936.00210714. Epub 2015 Jun 25.

44.

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.

Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, Antoniou KM.

Eur Respir Rev. 2015 Jun;24(136):327-39. doi: 10.1183/16000617.00009114. Review.

45.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Jul;109(7):904-13. doi: 10.1016/j.rmed.2015.04.010. Epub 2015 Apr 25.

46.

Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review.

Elia D, Torre O, Cassandro R, Caminati A, Harari S.

Eur J Intern Med. 2015 Jun;26(5):351-6. doi: 10.1016/j.ejim.2015.04.001. Epub 2015 Apr 17. Review.

PMID:
25899682
47.

The Health and Economic Burden of Air Pollution.

Franchini M, Mannucci PM, Harari S, Pontoni F, Croci E.

Am J Med. 2015 Sep;128(9):931-2. doi: 10.1016/j.amjmed.2015.03.021. Epub 2015 Apr 8. No abstract available.

PMID:
25863149
48.

Cellular interactions in the pathogenesis of interstitial lung diseases.

Bagnato G, Harari S.

Eur Respir Rev. 2015 Mar;24(135):102-14. doi: 10.1183/09059180.00003214. Review.

49.

Rare (pulmonary) disease day: "feeding the breath, energy for life!".

Harari S, Lau EM, Tamura Y, Cottin V, Simonneau G, Humbert M.

Eur Respir J. 2015 Feb;45(2):297-300. doi: 10.1183/09031936.00221914. No abstract available.

50.

Pulmonary hypertension in idiopathic pulmonary fibrosis does not influence six-minute walk distance: results from a retrospective study.

Harari S, Caminati A, Cassandro R, Conti S, Madotto F, Luisi F, Cesana G.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 5;31(4):297-305.

PMID:
25591141

Supplemental Content

Loading ...
Support Center